Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post results
The FDA approved a Ruxience biosimilar update, three Pfizer-linked oncology trials posted results, and several obesity, sleep apnea, and vaccine studies advanced.
This week's registry and regulatory updates for Pfizer span a biosimilar approval, three sets of newly posted oncology trial results, and several new or recruiting metabolic and vaccine studies.
- The FDA approved a supplemental biologics license application (SUPPL 20) for Ruxience, Pfizer's rituximab-pvvr biosimilar, available in 100MG/10ML and 500MG/50ML injectable strengths1, with the approval letter dated September 29, 2026.
- Results were posted for HER2CLIMB-05, a Phase 3 trial sponsored by Seagen, a wholly owned subsidiary of Pfizer2, testing whether tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer2. The trial enrolled 654 participants2 with progression-free survival as the primary endpoint.
- Results were also posted for a Pfizer-sponsored Phase 1b/2 study combining vepdegestrant with PF-07220060 in ER+/HER2- advanced or metastatic breast cancer3, which enrolled 71 participants3 and measured dose-limiting toxicities and objective response rate.
- A completed Phase 1/2 study of ARV-471 (vepdegestrant) alone and combined with palbociclib, sponsored by Arvinas Estrogen Receptor, Inc. with Pfizer as collaborator4, also posted results after enrolling 219 participants4 with ER+/HER2- locally advanced or metastatic breast cancer.
- VESPER-OSA 1, a Phase 3 Pfizer trial, began recruiting to test once-monthly berobenatide in adults with obstructive sleep apnea and overweight or obesity who use a breathing machine5, with planned enrollment of 258 participants.
- A new Phase 3 Pfizer trial called VESPER-SWITCH was registered, not yet recruiting, to study the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide6.
- A new Phase 1 Pfizer study was registered, not yet recruiting, to evaluate the pharmacokinetics, safety, and tolerability of PF-08653944 following a single subcutaneous dose in healthy Chinese adults with overweight or obesity7, with 16 participants planned.
- A Phase 3 COVID-19 vaccine trial sponsored by BioNTech, with Pfizer as collaborator, remains recruiting to test updated BNT162b2 vaccines in participants 5 through 64 years of age with risk factors for severe COVID-19, and participants 65 years of age and older8.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.